by Richard Daverman, PhD
May 13, 2014 -- NeoStem out-licensed exclusive China rights for its liver cancer treatment to Cellular Biomedicine Group of China. The patient-specific cancer immunotherapy, DC-TC, is ready to begin a Phase II trial in patients with hepatocellular carcinoma. CBMG will be responsible for the costs of the trial and most other aspects of the treatment’s development in China. NeoStem, however, will make the regulatory filings and manufacture DC-TC. If all goes well, NeoStem could receive up to $30 million in milestones. More details....
Stock Symbols: (NSDQ: NBS) (OTCQB: CBMG)
Help employers find you! Check out all the jobs and post your resume.
